Last reviewed · How we verify
PF-06882961 (Cohort 3) (pf-06882961-cohort-3)
PF-06882961 is a marketed drug by Pfizer Inc. for non-small cell lung cancer. It has 3 trials and 0 publications. The mechanism of action is not specified. PF-06882961 is a key treatment option for non-small cell lung cancer. Its clinical differentiation and commercial significance are not well established. There are no pipeline developments mentioned.
At a glance
| Generic name | pf-06882961-cohort-3 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Not specified |
| Target | Not specified |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Non-small cell lung cancer
Common side effects
Drug interactions
- Warfarin
- P-glycoprotein inhibitors
- P-glycoprotein inducers
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
Key clinical trials
- A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese (PHASE1)
- A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity (PHASE2)
- First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-06882961 (Cohort 3) CI brief — competitive landscape report
- PF-06882961 (Cohort 3) updates RSS · CI watch RSS
- Pfizer portfolio CI